Organophosphorus agents are easily absorbed via respiratory, gastrointestinal, and dermal routes, and inhibit the acetylcholine transferase enzyme, which is responsible for the majority of toxicity caused by organophosphates in the body. A comprehensive search was conducted across three prominent databases (Google Scholar, PubMed, and Science Direct) to identify relevant articles. The search focused on the keywords “MgSO4” or “magnesium sulfate” in conjunction with “organophosphate” or “organophosphate poisoning.” Inhibition of acetylcholine transferase enzyme results in the accumulation of acetylcholine in synapses and the stimulation of cholinergic receptors. As several studies have shown that magnesium sulfate (MgSO4) can inhibit the release of acetylcholine in the central and peripheral sympathetic and parasympathetic synapses, this study reviews the role of MgSO4 in the treatment of organophosphorus poisoning. The intravenous administration of MgSO4 exhibits favorable tolerability and clinical efficacy in alleviating cardiac toxicity associated with organophosphorus poisoning.

Chronic myeloid leukemia (CML), a myeloproliferative disorder caused by the over activity of BCR-ABL1 (breakpoint cluster region-Abelson), has been successfully treated by Tyrosine kinase inhibitors (TKIs). While imatinib is known as the first-line treatment of CML, in some cases other TKIs including dasatinib, nilotinib, bosutinib, and ponatinib may be preferred. Dasatinib, a second-generation TKI, inhibits multiple family kinases including BCR-ABL, SRC family kinases, receptor kinases, and TEC family kinases. It is effective against most imatinib-resistant cases except T315Imutation. Despite the superiority of dasatinib in its hematologic and cytogenetic responses in CML compared to imatinib, its potentially harmful pulmonary complications including pleural effusion (PE) and pulmonary arterial hypertension (PAH) may limit its use. Appropriate management of these serious adverse reactions is critical in both improving the quality of life and the outcome of the patient. In this narrative review, we will scrutinize the pulmonary complications of dasatinib and focus on the management of these toxicities.